Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 2
2020 3
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Foley P, Parker RA, de Angelis F, Connick P, Chandran S, Young C, Weir CJ, Chataway J; MS-SMART Investigators. Foley P, et al. Mult Scler Relat Disord. 2022 Jul;63:103925. doi: 10.1016/j.msard.2022.103925. Epub 2022 May 28. Mult Scler Relat Disord. 2022. PMID: 35671671 Free article. Clinical Trial.
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
Calvi A, Carrasco FP, Tur C, Chard DT, Stutters J, De Angelis F, John N, Williams T, Doshi A, Samson RS, MacManus D, Gandini Wheeler-Kingshott CA, Ciccarelli O, Chataway J, Barkhof F; MS SMART Investigators. Calvi A, et al. Neurology. 2022 Apr 26;98(17):e1783-e1793. doi: 10.1212/WNL.0000000000200144. Epub 2022 Mar 11. Neurology. 2022. PMID: 35277438
Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique.
Tur C, Grussu F, De Angelis F, Prados F, Kanber B, Calvi A, Eshaghi A, Charalambous T, Cortese R, Chard DT, Chataway J, Thompson AJ, Ciccarelli O, Gandini Wheeler-Kingshott CAM. Tur C, et al. Neuroimage Clin. 2022;33:102904. doi: 10.1016/j.nicl.2021.102904. Epub 2021 Dec 2. Neuroimage Clin. 2022. PMID: 34875458 Free PMC article.
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Solanky BS, John NA, DeAngelis F, Stutters J, Prados F, Schneider T, Parker RA, Weir CJ, Monteverdi A, Plantone D, Doshi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS-SMART Investigators. Solanky BS, et al. AJNR Am J Neuroradiol. 2020 Dec;41(12):2209-2218. doi: 10.3174/ajnr.A6809. Epub 2020 Nov 5. AJNR Am J Neuroradiol. 2020. PMID: 33154071 Free PMC article. Clinical Trial.
MS-SMART study: systematic sampling bias concerns - Authors' reply.
Chataway J, De Angelis F, Connick P, Parker RA, Doshi A, John N, Barkhof F, Sharrack B, Weir CJ, Chandran S; MS-SMART Investigators. Chataway J, et al. Lancet Neurol. 2020 Jun;19(6):479-480. doi: 10.1016/S1474-4422(20)30149-6. Epub 2020 May 26. Lancet Neurol. 2020. PMID: 32470412 Free article. No abstract available.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators. Chataway J, et al. Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network. Connick P, et al. BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944. BMJ Open. 2018. PMID: 30166303 Free PMC article. Clinical Trial.
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists. Marshall I, et al. J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30. J Neurol. 2018. PMID: 29846780 Free PMC article.
11 results